Ensidipine enasidenib usage and dosage

Ensidipine (enasidenib) is an anti-tumor drug used to treat relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutations. Ensidipine is used in 2017year8month1Nikkei USFDA approved the listing, but it has not been launched in China.

Ensidipine enasidenib usage and dosage:

The usual adult dose for acute myeloid leukemia is 100 mg orally once daily, treated until disease progression or unacceptable toxicity occurs, for patients without disease progression or unacceptable toxicity, treat for at least 6 months to allow for time for clinical response. While taking Follow all directions on the prescription label, read all medication guides or inserts, and take the medication exactly as directed. Drink plenty of fluids while takingensidipine. Take ensidipine tablets at the same time every day with or without food Do not crush, chew, or break ensidipine tablets Swallow whole tablets. If you vomit soon after taking ensidipine do not take another dose and take the next dose as planned. Store ensidipine at room temperature, away from moisture and heat. Store tablets in their original container with a hygroscopic preservative.

Patients receiving ensidipine developed symptoms of differentiation syndrome, which can be fatal if left untreated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusion, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multiorgan dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptoms resolve. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.